Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma.

BACKGROUND: Inhaled corticosteroids (ICS) are recommended in the treatment of asthmatic patients. They have been said to be efficacious in the treatment of asthma in respect to cortisol and bone metabolism. METHODS: The effects of the two inhaled corticosteroid, budesonide (BUD) and fluticasone propionate (FP) on bone metabolism, morning cortisol and their effects on the clinical parameters (FEV1, diurnal variation of peak expiratory flow rate = PEFR and log PC20) were examined in a group of 16 asthmatic patients. Eight patients used 800 micrograms/daily BUD and 8,400 micrograms/daily FP during 6 months period. RESULTS: Both BUD and FP improved clinical parameters as determined by FEV1 (p < 0.05) and PEFR (p < 0.01). There was no difference in respect to log PC20 values in either group (p > 0.05). Both treatments didn't change morning cortisol (p < 0.05). Both FP and BUD didn't change any indices of bone formation as determined by serum alkaline phosphatase, bone alkaline phosphatase, osteocalcin and carboxyterminal propeptide of type 1 procollagen and bone resorption as determined by urinary calcium and deoxypyridinoline (p > 0.05). In addition there was no significant effect on calcium and phosphate metabolism (serum calcium, phosphate and parathyroid hormone). CONCLUSION: As a result, having no adverse effect on bone metabolism and adrenal function, in the regard to clinical efficacy, FP is as effective as the double dose of BUD on PEFR and FEV1.

Fluticasone propionate and budesonide does not influence bone metabolism in the long term treatment of asthma

Background: inhaled corticosteroids (ICS) are recommended in the treatment of asthmatic patients. They have been said to be efficacious in the treatment of asthma in respect to cortisol and bone metabolism. Methods: the effects of the two inhaled corticosteroid, budesonide (BUD) and fluticasone propionate (FP) on bone metabolism, morning cortisol and their effects on the clinical parameters (FEV1, diurnal variation of peak expiratory flow rate = PEFR and log PC20) were examined in a group of 16 asthmatic patients. Eight patients used 800 μg/daily BUD and 8,400 μg/daily FP during 6 months period.Results: both BUD and FP improved clinical parameters as determined by FEV1 (p < 0.05) and PEFR (p < 0.01). There was no difference in respect to log PC20 values in either group (p > 0.05). Both treatments didn't change morning cortisol (p < 0.05). Both FP and BUD didn't change any indices of bone formation as determined by serum alkalin phosphatase, bone alkalin phosphatase, osteocalcin and carboxyterminal propeptide of type 1 procollagen and bone resorption as determined by urinary calcium and deoxypyridinoline (p > 0.05). ln addition there was no significant effect on calcium and phosphate metabolism (serum calcium, phosphate and parathyroid hormone). Conclusion: as a result, having no adverse effect on bone metabolism and adrenal function, in the regard to clinical efficacy, FP is as effective as the double dose of BUD on PEFR and FEV1 (AU)

Antecedentes: en el tratamiento de pacientes asmáticos se recomiendan corticoides inhalados (CSI).Se ha documentado que son eficaces en el tratamiento del asma con respecto al cortisol y al metabolismo óseo.Métodos: en un grupo de 16 pacientes asmáticos, se examinaron los efectos de dos corticoides inhalados, budesonida (BUD) y propionato de fluticasona (PF), sobre el metabolismo óseo, cortisol matutino y sus efectos sobre los parámetros clínicos (FEV1) y variación diurna de la tasa de flujo espiratorio máximo (PEFR y log PC20). Durante un período, de 6 meses, 8 pacientes utilizaron 800 g/día de BUD y 8, 400 g/día de PF.Resultados: tanto la BUD como el PF mejoraron los parámetros clínicos según lo determinado mediante el FEV1 (p 0,05). Ninguno de ambos tratamientos modificó los valores de cortisol matutino (p 0,05). Además, no se identificó un efecto significativo sobre el metabolismo del calcio y del fosfato (valores séricos de calcio, fosfato y paratormona).Conclusión: como consecuencia, puesto que el PF carece de efectos adversos sobre el metabolismo óseo y la función suprarrenal, desde un punto de vista clínico, es tan eficaz como una dosis doble de BUD sobre el PEFR y el FEV1 (AU)

T lymphocyte activation in bronchoalveolar lavage of patients with interstitial lung disease.

To study the role of T-lymphocytes in the patients with alveolitis due to interstitial lung disease (ILD), we have examined T cell populations in bronchoalveolar lavage (BAL) and peripheral blood (PB) of ten patients with ILD and six normal-controls via flow cytometry. The percentages of T-lymphocytes bearing the activation markers of HLA-DR (p < 0.01) and CD25 (p < 0.05) were significantly higher in BAL of ILD patients. There was no correlation between T lymphocytes subtypes and pulmonary functions and diffusion capacity (p > 0.05). In PB of ILD patients had less CD4+ T lymphocytes and CD19 cells (B lymphocytes) than controls (p < 0.05). This increased T-lymphocyte activation in BAL in contrast to PB suggested to have a role in the pathogenesis of the lung involvement in ILD.